Key result
Liver transplantation linked to acquired statin intolerance, suggesting donor-transmitted altered drug metabolism.
Why the study?
Does liver transplantation with a different cytochrome P-450 enzyme phenotype donor liver cause statin intolerance in a previously tolerant patient?
Case Report (n=1)
Does liver transplantation with a different cytochrome P-450 enzyme phenotype donor liver cause statin intolerance in a previously tolerant patient?
Pharmacogenomic differences in donor livers, such as cytochrome P-450 enzyme phenotypes, may lead to new drug intolerances post-transplant.
As pharmacogenomics testing is becoming more common, it can be used in more medical settings to assist in clinical decision making. This is a case study examining the implications of a patient having potentially different cytochrome P-450 enzyme phenotypes in the donor liver once transplanted. This patient tolerated statin therapy prior to liver transplantation but was intolerant to the same statin after liver transplant.
No takes yet. Share an insight, caveat, or question.
Michael J. Schuh (2026) conducted a case report in Liver transplant patient on statin therapy (n=1). Statin therapy post-liver transplant vs. Pre-transplant statin therapy was evaluated on Statin intolerance. A liver transplant patient developed intolerance to a previously tolerated statin post-transplant, suggesting donor liver cytochrome P-450 enzyme phenotypes may alter pharmacogenomic responses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: